-
Evaluating the Acceptability of Vignette Studies in Eliciting Utility Values for Rare Diseases: Perspectives From European HTA Agencies
Sep 9, 2025, 16:22 PM -
Fit-for-Purpose Real-World Data: Lessons From FDA QCARD and EMA Data Quality Framework
Sep 9, 2025, 16:22 PM -
Estimating Lost Life-Years and Quality-Adjusted Life-Years of Undertreatment of Patients With Renal Cell Carcinoma and Metastatic Pancreatic Cancer in England
Sep 9, 2025, 16:22 PM -
Comparing the Addition of Natural Language Processing (NLP) to US Electronic Health Records (EHRs): Insights Into Extracting Predicted Forced Vital Capacity (PpFVC) From Unstructured Clinical Notes
Sep 9, 2025, 16:22 PM -
Real-World Healthcare Resource Utilization in Patients With Metastatic Colorectal Cancer Treated With Trifluridine/Tipiracil Plus Bevacizumab or With Regorafenib
Sep 9, 2025, 16:22 PM -
Are Real-World Survival Outcomes in Metastatic Breast Cancer Transportable Between the US and Austria?
Sep 9, 2025, 16:22 PM -
The Cost of Inaction: Strengthening Nutrition in Frailty Guidelines Across Europe
Sep 9, 2025, 16:22 PM -
A Systematic Literature Review on Costs and Healthcare Resource Utilization in Spinal Muscular Atrophy
Sep 9, 2025, 16:22 PM -
Digital Health Literacy, Engagement, and the Economics of Health Behavior: Evidence from the US HINTS Survey
Sep 9, 2025, 16:22 PM -
Applying the Delphi Method: A Scoping Review in Healthcare Decision Making and HEOR
Sep 9, 2025, 16:22 PM -
Real-World Effectiveness of Oral Semaglutide in Thai Patients With Type 2 Diabetes: An Observational Single-Arm Multicenter Retrospective Cohort Study (REALISED)
Sep 9, 2025, 16:22 PM -
Adherence to Guidelines for the Treatment of Diabetes With Modern Antidiabetic Drugs in the Czech Republic: Clinical and Economic Impacts
Sep 9, 2025, 16:22 PM -
A Real-World Retrospective Study on the Utilization of Antifibrotic Drugs in Greece During the Period 2019-2023
Sep 9, 2025, 16:22 PM -
Activity of the French Economic and Public Health Evaluation Committee (CEESP): Retrospective of 10 Years of Economic Assessment on Health Products
Sep 9, 2025, 16:22 PM -
Quo Vadis? The Emerging Role of the Medicines and Healthcare Products Regulatory Agency (MHRA) in an Evolving Regulatory Landscape
Sep 9, 2025, 16:22 PM -
Cost-Utility Analysis (CUA) of Sepiapterin for Treatment of Phenylketonuria (PKU)
Sep 9, 2025, 16:22 PM -
Real-World Data for External Controls: Insights From EMA Regulatory Submissions
Sep 9, 2025, 16:22 PM -
Comparative Analysis of Patient-Reported Outcomes (PROs) in Asthma Biologic Late-Phase Studies and Approved Labels: Implications for Entry and Product Differentiation
Sep 9, 2025, 16:22 PM -
Financial Impact of Dementia Care on Thai Households: A Multicenter Study of Informal Care Costs and Contributing Factors
Sep 9, 2025, 16:22 PM -
A Cost-Effectiveness Evaluation of Blinatumomab Use in the Measurable Residual Disease-Negative Remission State to Treat Adults With Philadelphia-Chromosome–Negative B-cell Acute Lymphoblastic Leukemia in France
Sep 9, 2025, 16:22 PM
